Lixisenatide

FDA-approved product existsMetabolic ResearchWeight & metabolic

Awaiting review, BioHarmony verdict

Not yet scored. Queued for review; until then rely on the status and sources below.

What is Lixisenatide?

Lixisenatide is a component of FDA-approved Soliqua 100/33, a fixed-ratio insulin glargine and lixisenatide product for improving glycemic control in adults with type 2 diabetes.

Saved on this device only.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

Approved labelSOLIQUA 100/33 label for the fixed-ratio insulin glargine and lixisenatide product
PopulationAdults covered by the approved SOLIQUA 100/33 indication
DoseThe pen starts at 15 dose-steps for patients naive to basal insulin or using less than 30 units, or 30 dose-steps for patients using 30-60 units of basal insulin. The maximum 60 dose-steps provides 60 units insulin glargine and 20 mcg lixisenatide.
RouteSubcutaneous injection in the abdomen, thigh, or upper arm
FrequencyOnce daily within the hour before the first meal
DurationLong-term use within the approved indication with label-directed titration
PreparationReady-to-use 3 mL prefilled pen containing 100 units/mL insulin glargine and 33 mcg/mL lixisenatide; no reconstitution and do not dilute or mix.
Source: Dosage and Administration sections 2.1-2.5; Dosage Forms and Strengths section 3

Working with a vial? The reconstitution calculator covers mixing math, not dosing advice.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalFDA-approved product exists
CompoundingAn FDA-approved combination product exists; compounded copies are not FDA approved

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.